136 related articles for article (PubMed ID: 24745683)
21. Are gastrointestinal mucosal mast cells increased in patients with systemic mastocytosis?
Siegert SI; Diebold J; Ludolph-Hauser D; Löhrs U
Am J Clin Pathol; 2004 Oct; 122(4):560-5. PubMed ID: 15487454
[TBL] [Abstract][Full Text] [Related]
22. Clonality and molecular pathogenesis of mastocytosis.
Akin C
Acta Haematol; 2005; 114(1):61-9. PubMed ID: 15995326
[TBL] [Abstract][Full Text] [Related]
23. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
[TBL] [Abstract][Full Text] [Related]
24. Pathology of extramedullary mastocytosis.
Doyle LA; Hornick JL
Immunol Allergy Clin North Am; 2014 May; 34(2):323-39. PubMed ID: 24745677
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases.
Matito A; Álvarez-Twose I; Morgado JM; Sánchez-Muñoz L; Orfao A; Escribano L
Int Arch Allergy Immunol; 2011; 156(1):104-11. PubMed ID: 21447966
[TBL] [Abstract][Full Text] [Related]
26. Mastocytosis: Moving the Field to Precision and Personalized Medicine.
Castells MC
Immunol Allergy Clin North Am; 2018 Aug; 38(3):xv-xvii. PubMed ID: 30007470
[No Abstract] [Full Text] [Related]
27. Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis.
Chan IJ; Kasprowicz S; Tharp MD
Clin Exp Dermatol; 2013 Jul; 38(5):538-44. PubMed ID: 23777495
[TBL] [Abstract][Full Text] [Related]
28. Molecular alterations underlying eosinophilic and mast cell malignancies.
Sadrzadeh H; Abdel-Wahab O; Fathi AT
Discov Med; 2011 Dec; 12(67):481-93. PubMed ID: 22204765
[TBL] [Abstract][Full Text] [Related]
29. Mastocytosis: current concepts in diagnosis and treatment.
Escribano L; Akin C; Castells M; Orfao A; Metcalfe DD
Ann Hematol; 2002 Dec; 81(12):677-90. PubMed ID: 12483363
[TBL] [Abstract][Full Text] [Related]
30. The biology of Kit in disease and the application of pharmacogenetics.
Akin C; Metcalfe DD
J Allergy Clin Immunol; 2004 Jul; 114(1):13-9; quiz 20. PubMed ID: 15241338
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes.
Graves L; Stechschulte DJ; Morris DC; Lukert BP
J Bone Miner Res; 1990 Nov; 5(11):1113-9. PubMed ID: 2270775
[TBL] [Abstract][Full Text] [Related]
32. Current state of biology and diagnosis of clonal mast cell diseases in adults.
Alvarez-Twose I; Morgado JM; Sánchez-Muñoz L; García-Montero A; Mollejo M; Orfao A; Escribano L
Int J Lab Hematol; 2012 Oct; 34(5):445-60. PubMed ID: 22551157
[TBL] [Abstract][Full Text] [Related]
33. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.
Taylor ML; Sehgal D; Raffeld M; Obiakor H; Akin C; Mage RG; Metcalfe DD
J Mol Diagn; 2004 Nov; 6(4):335-42. PubMed ID: 15507672
[TBL] [Abstract][Full Text] [Related]
34. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
Moura DS; Sultan S; Georgin-Lavialle S; Pillet N; Montestruc F; Gineste P; Barete S; Damaj G; Moussy A; Lortholary O; Hermine O
PLoS One; 2011; 6(10):e26375. PubMed ID: 22031830
[TBL] [Abstract][Full Text] [Related]
35. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
Akin C
J Mol Diagn; 2006 Sep; 8(4):412-9. PubMed ID: 16931579
[TBL] [Abstract][Full Text] [Related]
36. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
37. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.
Won D; Chi HS; Shim H; Jang S; Park CJ; Lee JH
Leuk Res; 2013 Aug; 37(8):883-8. PubMed ID: 23683787
[TBL] [Abstract][Full Text] [Related]
38. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
39. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
